
New treatment option for patients with newly diagnosed multiple myeloma
The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT).
Darzalex subcutaneous regimen approved by European Commission – PharmaTimes